SOUTH SAN FRANCISCO, Calif. — August 29, 2025 — Leads & Copy — ALX Oncology Holdings Inc. (Nasdaq: ALXO) will participate in the Cantor Global Healthcare Conference 2025 and the H.C. Wainwright 27th Annual Global Investment Conference in New York.
The Cantor Global Healthcare Conference will feature a fireside chat and one-on-one meetings on Wednesday, September 3, 2025, in New York, NY. The fireside chat presentation will be at 9:45 AM ET. A webcast link is available.
The H.C. Wainwright 27th Annual Global Investment Conference will include one-on-one meetings on Tuesday, September 9, 2025, in New York, NY. A pre-recorded fireside chat presentation webcast link is available.
Webcasts of the fireside chats can be accessed in the Investors section of ALX Oncology’s website under the Events section of the Events and Presentations tab. Replays will be archived for up to 90 days.
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing therapies designed to treat cancer and extend lives. Its lead therapeutic candidate, evorpacept, is being evaluated across multiple clinical trials. ALX Oncology’s second candidate, ALX2004, is an EGFR-targeted antibody-drug conjugate and entered a Phase 1 trial in August 2025.
Investor Relations Contact:
Elhan Webb, CFA, IR Consultant
ewebb@alxoncology.com
Media Contact:
Audra Friis, Sam Brown Healthcare Communications
audrafriis@sambrown.com
(917) 519-9577
Source: ALX Oncology
